Silo Pharma Inc. Engages CFN Enterprises Inc. to Reach Psychedelics Investor Audience
Silo Pharma Inc. is a biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved medical conditions.
Whitefish, Montana--(Newsfile Corp. - February 10, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the addition of Silo Pharma Inc. (OTCQB: SILO) to its growing cannabis and psychedelics client roster.
Silo Pharma Logo
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6612/74051_3ca657af74697a49_001full.jpg
CFN Media will leverage its proprietary digital content platform and extensive distribution network-including its flagship CannabisFN and PsyIndex properties-to attract targeted retail, accredited and institutional investors to Silo Pharma Inc.
"Silo Pharma has made tremendous promise in growing its presence in the psychedelics industry," said CFN Media President Frank Lane. "Over the past couple of months, the company announced plans to commence a clinical study targeting Parkinson's disease, expanded its Scientific Advisory Board, inked a $1 million licensing deal, detailed its patent license agreement and entered into a sponsored research agreement."
Silo Pharma is focused on the development of psychedelic therapeutics for neurological disorders including fibromyalgia, post-traumatic stress disorder and Parkinson's disease. With biotech experience on the executive team, access to capital and a growing roster of partners, the company is well positioned to advance its clinical development programs.
"We are excited to be working with CFN Media, one of the leading voices in the psychedelic investment community," said Silo Pharma Inc. Chairman and CEO Mr. Eric Weisblum. "We expect to continue building out our clinical programs and intellectual property portfolio in 2021 and look forward to building long-term shareholder value."
The market for psychedelic drugs is projected to grow at a 16.3% CAGR to reach $6.85 billion by 2027, according to Data Bridge Market Research, driven by the increasing prevalence of mental health disorders and the growing acceptance of psychedelic drugs.
About Silo Pharma Inc.
Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. Silo's mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com.
About CFN Enterprises Inc.
CFN Enterprises Inc. (OTCQB: CNFN) is a digital media and ecommerce company focused on advancing businesses and brands in highly regulated emerging industries across the globe. CFN connects investors with new market opportunities while helping consumers find innovative products that enhance their lives. Learn more at www.cfnenterprisesinc.com.
CFN Enterprises Inc. Media Contact:
CFN Enterprises Inc.
+001 (833) 420-CNFN
[email protected]
FORWARD-LOOKING STATEMENT
Use of Forward-looking Statements
This press release may contain forward-looking statements from CFN Enterprises Inc. within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when CFN Enterprises Inc. describes Silo Pharma' business, and uses other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, CFN Enterprises Inc. is using forward-looking statements. These forward-looking statements are based on the current expectations of the management of CFN Enterprises Inc. only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products and services; or, loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of CFN Enterprises Inc. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, CFN Enterprises Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting CFN Enterprises Inc., reference is made to CFN Enterprises Inc.'s reports filed from time to time with the Securities and Exchange Commission.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74051